Insight

Mohammad Jad Moussa: Combining ICIs with Antiangiogenic Agents in Advanced Urothelial Cancer

Mohammad Jad Moussa/X

Dec 22, 2024, 11:44

Mohammad Jad Moussa: Combining ICIs with Antiangiogenic Agents in Advanced Urothelial Cancer

Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:

“Now in Bladder Cancer Journal of Bladder Cancer Advocacy Network.

Can Combining ICIs with Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer?

1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed.

Better patient selection.”

Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis

Authors: Mohammad Jad Moussa, Iuliia Kovalenko, Emanuele Crupi, Ekaterina Proskuriakova, Yimin Geng, Giuseppe Fallara, Raed Benkhadra, Daniele Raggi, Matthew T. Campbell, Pavlos Msaouel, Omar Alhalabi

Mohammad Jad Moussa

Bladder Cancer Advocacy Network Bladder Cancer Journal cancer Daniele Raggi Ekaterina Proskuriakova Emanuele Crupi Giuseppe Fallara Iuliia Kovalenko Matthew T Campbell Mohammad Jad Moussa Omar Alhalabi OncoDaily Oncology patient selection Pavlos Msaouel Raed Benkhadra Yimin Geng

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer